Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.
Operating profit increased by 6% measured in local currencies when adjusted for the cost of severance and the priority review voucher for oral semaglutide
In 2018 SmiLe met its annual goal of finding about ten new life science startup companies with a strong team, a high level of innovation and strong international market potential. SmiLe has thereby helped a total of 70 companies to develop their products for better health, including the current 22 member companies. Together, they have attracted a record amount of SEK 728 million in venture capital, 18 percent more than the previous year’s high figure.
SmiLe company Saga Diagnostics has been chosen following tough competition to be awarded a grant through Swelife’s “Project for better health, step 2” and will receive SEK 4.7 million. In addition to being a member of SmiLe Incubator, Saga is included in LU Holding’s portfolio of companies. Of the 22 projects that were evaluated, only eight receive funding and half of them come from Lund.
Sinntaxis in Lund has been awarded SEK 500,000 under the SME instrument phase 1 program within the EU Horizon 2020 framework. The grant money will be used to advance the business plan and the regulatory work to initiate a phase II clinical trial in stroke recovery.
Donations include $30 million to Communities In Schools, $10 million to City Year and $15 million to University of Chicago Education Lab. The contributions will significantly expand and strengthen programs to provide vulnerable children across the country with academic, social and emotional support to help them achieve their full potential.
In2cure’s founder has received SEK 950,000 from the Swedish Research Council for development of the drug candidate BioC, which will be used to promote wound healing. The In2cure project received consistently high scores in the Research Council’s assessment.